Dominant negative effects of Gln50Arg mutation in the EGF-1 domain of factor IX causes severe Hemophilia B affecting factor IX replacement therapy

Alprolix (eftrenonacog alfa) - SOBI, Sanofi

Feiba (human plasma derived anti-inhibitor coagulant complex) - Takeda

Rixubis (nonacog gamma) - Baxter Healthcare, Takeda

BeneFix (nonacog alfa) - Pfizer

https://isth2024.eventscribe.net/ajaxcalls/PresentationInfo.asp?PresentationID=1432597

T. T. van Duijl, T.T.; Kyra N. Smit; Nadia Freato; Joost C.M. Meijers; Alette Kooiker; Marlene Beijlevelt, MSc; Henrike M. Hamer; Maartje van den biggelaar; Samantha C. Gouw, MD PhD

May 18, 2024